Pharma Mar, S.a.u.

Parma Mar, S.a.

Pharma Mar, S.a.

Carmen Cuevas Marchante

Andrés Francesch Solloso

Fernando Albericio Palomera

Andrés Francesch

Ernest Giralt Lledó

Francisco Sánchez Sancho

Miriam Royo Expósito

Isabel Digón Juárez

Alfredo Pastor Del Castillo

Maria Angeles Ursa Pecharroman

Maria Jose Munoz Alonso

Juan Manuel Dominguez Correa

José Antonio Jiménez Guerrero

Maria Cristina Mateo Urbano

Christian Bailly

Marta Perez Alvarez

Carlos Del Pozo Losada

José Antonio Jimenez Guerrero

Christian Centre Oscar Lambret Bailly

Pilar Dept Of Organic Chemistry Lopez Rodriguez

Ernest Dept Of Organic Chemistry Giralt Lledo

José-Carlos Dept Of Organic Chemistry Jiminez Garcia

Miriam Dept Of Organic Chemistry Royo Exposito

Sonia Dept Of Organic Chemistry Varon Colomer

Ariadna Dept Of Organic Chemistry Fernandez Donis

Fernando Dept Of Organic Chemistry Albericio Palomera

Carolina Dept Of Organic Chemistry Gracia Cantador

Carolina Gracia Cantador

Sonia Varon Colomer

Pilar López Rodríguez

José-Carlos Jiménez García

Ariadna Fernandez Donis

Christina Mateo Urbano

Alberto Rodriguez Vincente

Maria Garranzo Garcia-Lbarrola

Pérez Carmen Murcia Murcia

Drug conjugates of formula [D-(X)-(AA)-(L)-]-Ab wherein:

Antibody drug conjugates

Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR', SOR&#x2032;, SOX, C(&#x2550;O)R&#x2032;, C(&#x2550;O)OR&#x2032;, C(&#x2550;O)NR&#x2032;, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R&#x2032; is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R&#x2033; is selected from the group consisting of H, OH, OR&#x2032;, OCOR&#x2032;, SH, SR&#x2032;, SOR&#x2032;, SOR&#x2032;, NO, NH, NHR&#x2032;, N(R&#x2032;), NHCOR&#x2032;, N(COR&#x2032;), NHSOR&#x2032;, CN, halogen, C(&#x2550;O)H, C(&#x2550;O)R&#x2032;, COH, COR&#x2032;, CHOR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; with the proviso that the compound is not compound 1, 3 or 4 of U.S. Pat. No. 5,514,708. The compounds have antitumour activity. A synthetic route is also provided. 

Total synthesis of myriaporones

New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof 

Antitumoral analogs of lamellarins

Growing community of inventors

Madrid, Spain

Carmen Cuevas Marchante